Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Statera Biopharma Inc (STAB)

OTC Markets
Currency in USD
Disclaimer
0.001
0.000(0.00%)
Closed
STAB Scorecard
Trading near 52-week Low
Fair Value
Unlock Value
Day's Range
0.0010.001
52 wk Range
0.0010.038
Prev. Close
0.001
Open
0.001
Day's Range
0.001-0.001
52 wk Range
0.001-0.038
Volume
300
Average Vol. (3m)
3,012
1-Year Change
-94.12%
Shares Outstanding
72,584,254
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about STAB?
Vote to see community's results!
or

Statera Biopharma Inc Company Profile

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The Company has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.